Antithrombotic dose: Some observations from published clinical trials

Area of Science:

• Pharmacology
• Clinical Medicine
• Drug Development

Background:

• Clinical antithrombotic doses require a balance between therapeutic efficacy and patient safety.
• The derivation of current clinical doses from preclinical and clinical data is not well-documented in existing literature.
• Limited large randomized controlled trials (RCTs) exist that compare varying antithrombotic doses against placebo.

Purpose of the Study:

• To investigate the evidence base for current clinical dosing of antithrombotic agents.
• To evaluate the dose-response relationship for antithrombotic efficacy and safety.
• To assess whether lower antithrombotic doses could maintain efficacy while improving safety.

Main Methods:

• Review of published literature, focusing on randomized controlled trials (RCTs) of antithrombotic agents.
• Analysis of dose selection strategies in RCTs for newer antithrombotics, particularly in relation to noninferiority trials.
• Examination of data from RCTs regarding the efficacy and safety of aspirin and direct oral anticoagulants at reduced doses.

Main Results:

• RCT doses for newer antithrombotics may be selected to maximize the likelihood of demonstrating noninferiority against established agents.
• Aspirin demonstrates antithrombotic efficacy at daily doses below 75 mg.
• Direct oral anticoagulants show stroke risk reduction in coronary disease patients at doses significantly lower (1/4) than those recommended for atrial fibrillation.

Conclusions:

• Lower antithrombotic doses, compared to current recommendations, appear to be safer.
• Substantial antithrombotic efficacy can be maintained with these lower doses.
• Further research into optimized dosing strategies for antithrombotic agents is warranted to improve patient outcomes.